Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access [Ga-68] PSMA-11 PET Imaging

NCT04800068
View directory record Official record
Conditions
Prostate Cancer
Interventions
[Ga-68] PSMA-11 PET/CT, [Ga-68] PSMA-11 PET/MR
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Feasibility Study: Educational Genetic Test Video

NCT06166758
View directory record Official record
Conditions
Prostate Cancer, Education
Interventions
Educational Video
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 30, 2026, 10:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

COQ10 and Vitamin E for Off-Target Radiation Toxicity

NCT07668284
View directory record Official record
Conditions
Prostate Cancer, Uterine Cancer, Cervical Cancer, Anal Cancer
Interventions
Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00003238
View directory record Official record
Conditions
Prostate Cancer
Interventions
perillyl alcohol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
8
States / cities
Freeport, Illinois • Green Bay, Wisconsin • Janesville, Wisconsin + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional

Periprostatic Neurolysis in Prostate Cancer

NCT07100847
View directory record Official record
Conditions
PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
Interventions
Periprostatic neurolysis with dehydrated alcohol (ethanol)
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumors
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Results available

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

NCT06067295
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Not listed Phase 2 Interventional

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

NCT03141671
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH, Bicalutamide, Salvage radiation, Abiraterone, Prednisone, Apalutamide
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

NCT04019964
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 4 Interventional

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

NCT00063609
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Metformin in Castration-Resistant Prostate Cancer

NCT01215032
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Internal Radiation Therapy in Treating Patients With Prostate Cancer

NCT00573833
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, quality-of-life assessment, brachytherapy
Other · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

NCT01483586
View directory record Official record
Conditions
Prostate Cancer
Interventions
Kanglaite gelcap
Drug
Lead sponsor
KangLaiTe USA
Industry
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

NCT00151086
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Vinorelbine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00028769
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis

NCT06830265
View directory record Official record
Conditions
Prostate Cancer Screening
Interventions
Novel needle biopsy catheter (test)
Device
Lead sponsor
Uro-1 Medical
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Hardeeville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Focal Prostate Radio-Frequency Ablation

NCT02328807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radio-Frequency Ablation (RFA)
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Decision Impact Trial of the ExoDx Prostate (IntelliScore)

NCT03235687
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
ExoDx Prostate (IntelliScore)
Diagnostic Test
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 30, 2026, 10:37 PM EDT